This pharma stock has zoomed 57% thus far in 2024; Citi sees more upside

Q: How long will it take to read this news story?

The story "This pharma stock has zoomed 57% thus far in 2024; Citi sees more upside" has 553 words across 16 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "This pharma stock has zoomed 57% thus far in 2024; Citi sees more upside" was covered 4 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 249 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22992767</li><li>URL: https://beamstart.com/news/this-pharma-stock-has-zoomed-17286270563303</li></ul>

Business Standard Logo Business Standard 4h ago

This pharma stock has zoomed 57% thus far in 2024; Citi sees more upside - Business Standard

Quick Summary:

By comparison, Sun Pharmaceutical Industries (up 51 per cent), Cipla (30 per cent), Torrent Pharmaceuticals (52 per cent), and Zydus Lifesciences (54 per cent) have rallied up to 54 per cent thus far in CY24.

Products like GLP-1, Ribociclib, Upadacitinib etc., also indicate that the company is now making or is expected to make APIs of top products of companies like Eli Lilly, Novartis, Merck, Abbvie, among others.

Thus far in the calendar year 2024 (CY24), Divi’s Lab share has outperformed the market as well as its peers by surging 57 per cent as compared to a near 13-per cent rise in the BSE Sensex.